Overview


According to FutureWise analysis the market for Ischemic Cerebral Stroke Prevention Therapeutics is expected to register a CAGR of 6.32% from 2024-2032.

The ischemic stroke occurs when there is an obstruction in the blood vessel that supplies blood to the brain. Ischemic strokes account for about 87 percent of all stroke cases, and uncontrolled hypertension is the main cause. In essence, an ischemic stroke is caused by a weak blood vessel that ruptures, causing blood to leak into the brain. There are two types of ischemic cerebral strokes: embolic and thrombotic. During atherosclerosis, an artery is blocked by a blood clot, resulting in fatty deposits. When a blood clot forms outside the brain and travels to the bloodstream, it is called an embolus stroke (emboli). Technological advancements leading to the development of advanced surgical devices as well as the increasing prevalence of ischemic strokes have led to a demand for more effective stroke management or treatment worldwide. The major goal of ischemic cerebral stroke prevention is to restore blood flow as quickly as possible. Ischemic stroke treatments include intravenous thrombolysis and intra-arterial mechanical thrombectomy, which includes stent retrieval devices. According to the American Stroke Association, few recommendations related to preventing an ischemic stroke include sleep apnea screening, smoking cessation, and oral anticoagulants especially in patients with non-valvular atrial fibrillation.

A stroke is a deadly condition that is age related and should be prevented. In general, there are two ways to control this: Primary Prevention of Stroke and Secondary Prevention of Stroke.
The primary prevention of stroke can be achieved with the use of antihypertensive drugs, anticoagulants-warfarin; antiplatelet agents, and statins. Smoking, hypertension, diabetes, sickle cell disease, body fat, and hypertension are the leading causes of Ischemic Cerebral Stroke. Other home remedies include self-monitoring of blood pressure in hypertensive patients and proper sleep.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Ischemic Cerebral Stroke Prevention Therapeutics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Ischemic Cerebral Stroke Prevention Therapeutics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Johnson & Johnson (Cordis Corporation)
  • Boston Therapeutics, Inc.
  • Edge Therapeutics, Inc.
  • Zocere, Inc.
  • Lundbeck
  • ThromboGenics
  • Vernalis
  • Bayer
  • Bristol-Myers Squibb
  • Boehringer Ingelheim

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Type

  • Anticoagulation Therapy
    • Warfarin
    • Heparin
    • Revascularization
    • Reperfusion
    • Eminase
    • Retavase
    • Streptase
    • Others
  • Antiplatelet
  • Aspirin
  • Clopidogrel
  • Dipyridamole
  • Ticlopidine
  • Neuroprotective
  • Acetyl-L-carnitine
  • Citicoline (CDP-Choline)

By End User

  • Hospitals
  • Clinics
  • Palliative Care
  • Ambulatory Surgery Centers

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Ischemic Cerebral Stroke Prevention Therapeutics Market By Drug Type, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Ischemic Cerebral Stroke Prevention Therapeutics Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Ischemic Cerebral Stroke Prevention Therapeutics Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Ischemic Cerebral Stroke Prevention Therapeutics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Ischemic Cerebral Stroke Prevention Therapeutics Market, By Drug Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Anticoagulation Therapy
         1.1. Warfarin
         1.2. Heparin
         1.3. Revascularization
         1.4. Reperfusion
         1.5. Eminase
         1.6. Retavase
         1.7. Streptase
         1.8. Others
        2. Antiplatelet
        3. Aspirin
        4. Clopidogrel
        5. Dipyridamole
        6. Ticlopidine
        7. Neuroprotective
        8. Acetyl-L-carnitine
        9. Citicoline (CDP-Choline)

  • 8.   Ischemic Cerebral Stroke Prevention Therapeutics Market, By End User Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospitals
        2. Clinics
        3. Palliative Care
        4. Ambulatory Surgery Centers

  • 9.   North America Ischemic Cerebral Stroke Prevention Therapeutics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 10.   Latin America Ischemic Cerebral Stroke Prevention Therapeutics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 11.   Europe Ischemic Cerebral Stroke Prevention Therapeutics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 12.   Asia Pacific Ischemic Cerebral Stroke Prevention Therapeutics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 13.   Middle East and Africa Ischemic Cerebral Stroke Prevention Therapeutics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Johnson & Johnson (Cordis Corporation)
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Boston Therapeutics, Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Edge Therapeutics, Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Zocere, Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Lundbeck
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. ThromboGenics
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Vernalis
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Bayer
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Bristol-Myers Squibb
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Boehringer Ingelheim
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients